Patient Journey Timeline
Diagnosis, biopsies, lines of therapy and RECIST response on one rail. Progression events are unmistakable, so the board starts from the right context.
Longitudinal View
Molecular Tumour Board Platform
Every Tumour Board Decision — Documented, With the Evidence Attached.
Animisa brings the patient journey, the molecular report, published approvals, guideline entries and trial listings into one workspace, and records the board's decision in a signed, audit-ready document. The decision is the physicians'; the paperwork is ours.
Contact- EMA · FDA
- Approval Status Inline
- NCCN · ESMO
- Guideline Entries Inline
- PubMed-Cited
- Every Statement Sourced
Approved Indications
Board Decisions
AI-Drafted Text
Platform
One Workspace for the Whole Board
Longitudinal context, EHR-grade density and published evidence with its sources — in one clinical workspace.
Molecular Tumor Board Workspace
Regimens listed with their regulatory approval status, NCCN/ESMO guideline entries and the published trial results behind them — every statement cited to PubMed.
Published Evidence, Attached
Board Minutes & Documents
Agenda, attendance, the recorded decision and its rationale, a signed board summary and a plain-language letter for the patient — in Greek or English.
Audit-Ready Documentation
Sourced Evidence
Every Entry Shows Its Source
Regimen summaries are compiled from PubMed, NCCN, ESMO and regulatory labels, with PMID citations on every statement. Optional AI drafting (bring your own EU provider key) summarises published abstracts; uncited sentences are suppressed and every draft is marked for physician review.
Trial Listings
Open trials retrieved by tumour type and biomarker, with listed eligibility criteria and distance to the nearest site.
Prior-Authorization Letters
Medical-necessity letters assembled from the record, with AI-drafted paragraphs marked for physician review.
Raw Variant Transparency
Full NGS call set with VAF, depth and reported classification — nothing hidden behind the summary.
On-Premise, Your Data
Runs on a clinic workstation or server. Encrypted at rest, audit-logged, no cloud account required.
Roadmap
Clinical Edition · subject to CE marking
Patient-Specific Decision Support Is Coming — As a Medical Device
Scoring, ranking and alerting regimens for an individual patient is software with a medical purpose under Regulation (EU) 2017/745. Those functions are being prepared as a separate Clinical Edition and will be offered only after conformity assessment and CE marking. The Workflow Edition available today contains none of them.
Fit Score & Therapy Ranking
Patient-specific scoring of regimens against genotype, prior lines and comorbidities.
Not available · pending CE
Contraindication & Resistance Alerts
Co-mutation and PGx/HLA warnings surfaced per patient.
Not available · pending CE
Trial Eligibility Scoring
Criterion-by-criterion match against the patient record.
Not available · pending CE
Not a Medical Device
The Workflow Edition stores, retrieves and documents. It does not score, rank or recommend therapies for a patient; clinical decisions rest with the physician and the tumour board.
GDPR by Design
On-premise, encrypted at rest, role-based access, every record access audit-logged. Third-party look-ups use identifiers and biomarker names only — never patient data.
Source Currency
NCCN and ESMO guideline versions and label dates are pinned and shown on every document.